Latest News in the pharma Industry

Research & Development

Novartis broadens immuno-oncology pipeline with acquisition of Admune Therapeutics

Novartis broadens immuno-oncology pipeline with acquisition of Admune Therapeutics

21 Oct 2015

With four programs currently in clinical trials and five more expected to enter the clinic by the end of 2016, Novartis has rapidly built a robust portfolio of programs focused on stimulating the body's immune system to combat cancers.

Read more 
Synta announces termination for futility of ganetespib Phase III GALAXY-2 trial in lung cancer

Synta announces termination for futility of ganetespib Phase III GALAXY-2 trial in lung cancer

21 Oct 2015

IDMC concludes that the addition of ganetespib to docetaxel is unlikely to demonstrate a statistically significant improvement in the primary endpoint of overall survival compared to docetaxel alone.

Read more 
Shire provides update on next steps for lifitegrast in light of FDA CRL

Shire provides update on next steps for lifitegrast in light of FDA CRL

20 Oct 2015

Company plans to refile lifitegrast submission in the first quarter of 2016.

Read more 
Shire receives FDA complete response letter for lifitegrast NDA and plans to respond with OPUS-3 trial

Shire receives FDA complete response letter for lifitegrast NDA and plans to respond with OPUS-3 trial

19 Oct 2015

Topline results from OPUS-3 Trial expected before year-end.

Read more 
Allergan completes AqueSys acquisition, adding XEN45 minimally invasive implantable shunt for glaucoma

Allergan completes AqueSys acquisition, adding XEN45 minimally invasive implantable shunt for glaucoma

19 Oct 2015

XEN45 approved in global markets and in in late-stage development in the US.

Read more 
Eleven Biotherapeutics completes enrolment in pivotal Phase III study of isunakinra (EBI-005) in patients with allergic conjunctivitis

Eleven Biotherapeutics completes enrolment in pivotal Phase III study of isunakinra (EBI-005) in patients with allergic conjunctivitis

16 Oct 2015

Eleven granted isunakinra as the international nonproprietary name for EBI-005.

Read more 
Lilly to discontinue development of evacetrapib for high-risk atherosclerotic cardiovascular disease

Lilly to discontinue development of evacetrapib for high-risk atherosclerotic cardiovascular disease

12 Oct 2015

Phase III trial terminated due to insufficient efficacy.

Read more 
Eli Lilly expands New York City R&D site

Eli Lilly expands New York City R&D site

9 Oct 2015

Expansion will power immuno-oncology discovery and research collaborations.

Read more 
Boehringer's investigational biologic cleared skin better, faster and for longer than ustekinumab in Phase II psoriasis study

Boehringer's investigational biologic cleared skin better, faster and for longer than ustekinumab in Phase II psoriasis study

9 Oct 2015

Nearly triple the percentage of patients maintained completely clear skin on BI 655066 after nine months, compared to ustekinumab.

Read more 
Concert Pharmaceuticals announces $8 million milestone from Celgene

Concert Pharmaceuticals announces $8 million milestone from Celgene

9 Oct 2015

Phase I clinical evaluation of CTP-730 completed.

Read more 
Horizon Discovery Group in-licenses oncology programme from Servier and enters option agreement

Horizon Discovery Group in-licenses oncology programme from Servier and enters option agreement

7 Oct 2015

Horizon will exploit its translational genomics and combination sciences platform to define optimum approaches to treatment and identify cancer patient populations most likely to respond.

Read more 
Bi-bi breast cancer — new in vitro treatment study begins in oxford

Bi-bi breast cancer — new in vitro treatment study begins in oxford

7 Oct 2015

Redesigned bi-specific antibodies may offer new hope against secondary breast cancer.

Read more